Psilocybin Therapy Tourism 2026: Oregon vs Jamaica vs Netherlands (Cost, Legality, Clinical Setup)

You've tried two antidepressants that didn't work and a third that blunted every emotion until you couldn't recognise yourself. You read the Johns Hopkins psilocybin studies at 2 a.m. and cried with something that felt like hope for the first time in a year. You found an Oregon service center but the waitlist stretches four months and the quoted cost is $3,200 out of pocket with no insurance coverage. You saw a Jamaican retreat advertised on Instagram for $6,800 and couldn't tell if it was legitimate therapy or a luxury vacation with mushrooms. You heard "legal truffles in Amsterdam" and assumed that meant a coffee shop with no clinical structure whatsoever.

This guide gives you the actual 2026 picture. Three legal pathways, real prices in real currencies, the exact legal statute behind each, the clinical evidence from MAPS and Johns Hopkins, and the contraindication checklist every legitimate provider uses before you set foot in a session room. Travel Anywhere is the AI-powered travel planning platform at travelanywhere.chat that helps conscious health travelers compare wellness destinations, clinical setups, and logistics in one workflow, and this is exactly the comparison it was built for.

TL;DR: Three legal frameworks exist for psilocybin therapy in 2026. Oregon operates under Measure 109 (ORS Chapter 475A), the world's first state-regulated psilocybin services program: preparation + session + integration from $1,500 to $4,500 total, no psychiatric diagnosis required, facilitators must hold a state license. Jamaica has never scheduled psilocybin or psilocin under its Dangerous Drugs Act (Chapter 201B), making mushroom-based retreats fully unregulated and legal: structured multi-day programs cost $2,500 to $8,500 (MycoMeditations 8-day program: $6,250 shared). The Netherlands bans psilocybin mushrooms under its Opium Act but exempts sclerotia (truffles), creating a legal-by-omission pathway: guided truffle ceremonies cost €350 to €1,200 for group sessions, €1,700+ for private sessions. Johns Hopkins Phase 2 data shows 58% depression remission at 12 months. MAPS-adjacent psilocybin research shows Hedges' g effect size of -1.27 in treatment-resistant depression. WHO-rated contraindications (personal or family history of psychosis, current lithium use, uncontrolled cardiovascular disease) are enforced by all three legitimate providers. No legal jurisdiction covers psilocybin therapy under standard travel insurance. One poorly screened session can trigger a medical evacuation that costs more than the entire program.

Key Takeaways

1. Oregon is the only state-regulated program with mandatory facilitator licensing: Under ORS Chapter 475A (Measure 109), every service center must be licensed, every facilitator must complete a state-approved training program, and every client undergoes a mandatory preparation session before dosing. The Oregon Health Authority adopted updated rules effective January 1, 2026. Cost: $1,500–$4,500 total per client.
2. Jamaica is legal, not regulated: Psilocybin and psilocin do not appear on Jamaica's Dangerous Drugs Act Schedule, a colonial-era gap that has remained intact. Retreats are legal but face zero state clinical oversight: quality, screening protocols, and integration support depend entirely on the retreat operator.
3. Netherlands truffles are legal by a specific technicality: The 1999 Dutch Opium Act banned psilocybin mushrooms (aboveground fruiting bodies). Sclerotia (underground storage bodies of the same fungi, sold as "magic truffles") were not listed. That omission has never been legislatively corrected, making truffles legal to purchase, possess, and consume as of 2026.
4. Clinical evidence for treatment-resistant depression (TRD) is strong: A pilot trial published in Journal of Psychopharmacology (2025) found a mean depressive symptom reduction of -7.14 points with Hedges' g = -1.27 in TRD patients. A 12-month Veterans study (ScienceDirect, 2025) found 58% in depression remission at 12 months. The EPISODE randomized clinical trial (PubMed, 2026) confirms the efficacy signal in TRD.
5. Contraindications are non-negotiable: Personal or family history of schizophrenia, schizoaffective disorder, or bipolar I; current use of lithium or MAOIs; uncontrolled cardiovascular disease; active suicidality. Every accredited provider runs a medical screening questionnaire. Self-screening failures are the primary driver of adverse events across all three jurisdictions.
6. Integration support is what separates a clinical intervention from a recreational experience: Oregon mandates integration sessions under state rules. The best Jamaican and Dutch providers offer structured post-session support. The worst offer none. Ask any provider to specify the integration protocol before booking. It is the single best proxy for overall quality.

How does this compare to other medical tourism decisions? Read the bariatric surgery tourism cost and safety breakdown.

Photo by Abhinav Gorantla on Unsplash

What Are the Three Legal Psilocybin Therapy Pathways in 2026?

The global legal landscape for psilocybin therapy is commonly misunderstood as a binary: legal or illegal. The reality is a patchwork of three meaningfully different frameworks, each with different clinical structure, cost, and legal basis.

Pathway 1: Oregon Measure 109 (state-regulated service model). Oregon's Measure 109, codified as ORS Chapter 475A, created a first-in-the-world state-licensed psilocybin services framework. As of 2026, the Oregon Health Authority licenses service centers, facilitators, manufacturers, and testing labs. Clients do not need a clinical diagnosis. No prescription is required. Sessions use OHA-standardized psilocybin products manufactured by licensed Oregon producers. The program is explicitly a "supervised experience" model, not a prescription drug model, which is why it was able to pass at the ballot level without FDA involvement.

Pathway 2: Jamaica retreat model (legal by omission, unregulated). Jamaica became a signatory to the 1971 UN Convention on Psychotropic Substances but exercised its national discretion in scheduling: psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and psilocin are not listed in the Jamaican Dangerous Drugs Act (Chapter 201B). This is not a recent reform. It is the original colonial-era schedule, never updated to add psychedelics. As a result, psilocybin mushroom retreats in Jamaica operate legally but without any state clinical oversight equivalent to what Oregon provides.

Pathway 3: Netherlands truffle model (legal by technicality). The Netherlands amended its Opium Act in 1999 to add psilocybin mushrooms (paddo's) to List I controlled substances. Sclerotia (the underground mycelial storage structures of the same organisms) were not specifically named. Dutch authorities and courts have consistently maintained that this omission is legally operative: truffles remain legal to sell, possess, and consume as of 2026. Hundreds of licensed "truffle ceremony" businesses operate openly in Amsterdam and across the Netherlands.

The key distinction: Oregon is the only pathway with state-mandated clinical standards for both the provider and the experience. Jamaica and the Netherlands have fully legal environments where quality varies from clinical-grade to tourist-grade, entirely determined by the operator.

How Do Oregon Service Centers Work Under Measure 109?

Oregon's Measure 109 framework, as updated under OHA rulemaking effective January 1, 2026, mandates a three-stage client journey: preparation, administration, and integration.

Preparation sessions (minimum one session required under OAR Chapter 333, Division 333) are conducted by a licensed facilitator. The facilitator reviews medical and psychiatric history, administers a standardized health screening, confirms no contraindications, discusses intentions and expectations, and develops a session plan. These sessions are typically conducted in person and cost $100–$300 each depending on facilitator pricing.

The psilocybin administration session takes place at a licensed service center: a dedicated facility that must meet OHA environmental standards (controlled lighting, sound, comfortable reclining surface, emergency protocols). The facilitator remains present for the full 4–8 hour session. Psilocybin product is manufactured by licensed Oregon producers at standardized potencies, meaning clients receive a known dose rather than variable dried mushroom material. Session costs range from $500 to $2,000 depending on the service center and dose level.

Integration sessions follow the administration session and help clients process and apply the experience. Oregon rules require integration to be offered; how extensively varies by provider.

Oregon Health Authority (OAR 333-333), 2026 rule text: "A facilitator may not administer psilocybin to a client unless the facilitator has conducted a preparation session and determined, based on the health screening, that the individual does not present a contraindication to psilocybin services."

Cost summary for Oregon (2026): Preparation session $100–$300 | Administration session $500–$2,000 | Integration session(s) $100–$300 | Total realistic budget: $1,500–$4,500. No insurance coverage is available. Insurance companies do not cover Measure 109 services under current policies, as the OHA framework sits outside the prescription drug system.

Access limitation: As of early 2026, approximately one-third of licensed Oregon service centers have closed, largely due to high operating costs (licensing alone runs $10,000 annually, plus insurance premiums 3x higher than standard medical businesses per OPB reporting). Wait times at remaining centers are running 4–12 weeks. Portland-area centers are more available than rural Oregon centers.

How Are Jamaican Psilocybin Retreats Legally Structured?

Jamaica's legal environment means psilocybin retreats operate openly and advertise directly to international visitors with no legal risk to either the operator or the participant under Jamaican law. What they are not (and this is crucial) is clinically regulated.

The established retreat operators have developed their own clinical standards to fill the regulatory vacuum. The best of them are robust. The worst are not.

MycoMeditations (operating since 2015, based in Treasure Beach, St. Elizabeth Parish) offers an 8-day program with three psilocybin sessions, integration circles, group therapy facilitation, and medical screening administered by a licensed physician. Pricing in 2026: $6,250 per person shared, $9,600 single occupancy. Their facilitators include licensed therapists and trauma specialists.

ONE Retreats (Jamaica) uses a similar model with preparation sessions, physician medical screening, and structured group integration. Full Moon Retreat pricing (May 2026): available on request.

Beckley Retreats Jamaica draws on the Beckley Foundation's clinical research heritage. Amanda Feilding's Beckley Foundation has co-authored peer-reviewed psilocybin studies. Retreat pricing ranges from approximately $3,500 to $7,500 depending on program length.

Budget-tier Jamaica retreats (some priced as low as $2,500) may provide fewer preparation and integration sessions, less experienced facilitation, and no physician medical screening. The cost gap between a $2,500 and a $7,500 Jamaica retreat is almost entirely a difference in clinical infrastructure, not accommodation quality.

From Jamaicaexperiences.com's 2026 pricing guide: "What you're actually paying for is the hours of skilled facilitation and clinical support around the medicine experience itself. The truffle or the mushroom is never the expensive part."

Legal status sourced: Dangerous Drugs Act of Jamaica, Chapter 201B. The scheduled substances list does not include psilocybin, psilocin, or mushrooms of the genus Psilocybe. UNODC Bulletin of Narcotics confirms Jamaica's adherence to the 1971 Convention but notes that national scheduling implementation varies by signatory.

Photo by Greg Rosenke on Unsplash

Can I Buy Truffles Legally in the Netherlands?

Yes, with important caveats about what "legally" means and how widely that legal standard extends.

Under the Dutch Opium Act (Opiumwet), Schedule I lists psilocybin mushrooms (paddo's) as controlled substances. Psilocybin truffles (sclerotia of Psilocybe tampanensis, P. atlantis, P. mexicana, and other species) are not named. Dutch courts and the Openbaar Ministerie (Public Prosecution Service) have treated this omission as operative: truffles are not a controlled substance and can be legally bought at smart shops and through licensed truffle ceremony operators throughout the Netherlands.

The Trimbos Institute (the Dutch national institute for mental health and addiction, analogous to NIDA) publishes annual drug use data and harm-reduction guidance. Their 2023 report notes that truffle use is concentrated in Amsterdam's "ceremony" market, with most participants being international visitors seeking guided therapeutic experiences rather than recreational users.

Trimbos Institute, National Drug Monitor 2023: "The organized truffle retreat market has professionalised substantially since 2018. The majority of operators offering guided truffle ceremonies now require advance medical screening and provide post-ceremony support."

What a Netherlands truffle ceremony looks like in practice (2026):

Licensed operators such as Synthesis (Amsterdam), Conscious Growth EU, and Truffle Ceremony NL offer structured day-long or weekend experiences. A typical format: intake screening form + facilitator consultation (usually remote, 48–72 hours before); ceremony day with 5–8 hours of guided experience (music, eye masks, physical support); integration circle in the hours after the experience; optional follow-up video call.

Truffles are sold separately by the gram. A therapeutic dose (25–35 grams fresh) costs approximately €30, paid directly at the ceremony location. The ceremony fee covers facilitation, space, support, and integration.

Cost summary for Netherlands (2026): Group truffle ceremony €350–€1,200 | Private one-on-one session €1,700+ | Truffle purchase ~€30 (separate). The Netherlands is the lowest-cost of the three legal pathways by a significant margin for group formats.

Limitation: No state clinical licensing of facilitators exists in the Netherlands. Quality control depends entirely on operator self-regulation. The Dutch Smart Shops Association and platform-based vetting (Retreat Guru, BookRetreats) are the primary quality signals available to international visitors.

What Does the MAPS Clinical Evidence Show?

The clinical evidence base for psilocybin is primarily anchored at two institutions: Johns Hopkins Center for Psychedelic and Consciousness Research and COMPASS Pathways (the commercial entity behind Phase 2b and Phase 3 trials). MAPS (Multidisciplinary Association for Psychedelic Studies) has focused primarily on MDMA-assisted therapy, but MAPS-affiliated researchers and the broader clinical literature provide the evidence base psilocybin travelers should understand before booking.

Treatment-Resistant Depression (TRD): The most recent and methodologically rigorous data:

• A 2025 pilot clinical trial in the Journal of Psychopharmacology (Meikle et al., Sagepub) found a mean depressive symptom reduction of -7.14 points (Hedges' g = -1.27) in TRD patients receiving psilocybin with psychotherapeutic support: a large effect size by clinical standards.
• A 12-month open-label pilot study of US military Veterans with severe TRD (ScienceDirect, 2025) found 58% of participants in depression remission at 12 months, with some attenuation of effect from 9 to 12 months.
• The EPISODE randomized clinical trial (PubMed, 2026) confirmed a clinically meaningful reduction in depressive symptoms in TRD, though the primary outcome did not reach statistical significance, underscoring that psilocybin therapy produces strong responses in a meaningful subset rather than universal outcomes.
• A network meta-analysis published in ScienceDirect (2024) covering multiple randomized placebo-controlled trials of psilocybin in Major Depressive Disorder found consistent dose-dependent efficacy signals, with 25 mg psilocybin showing the strongest effect.

PTSD: Evidence is earlier-phase but promising. A 2025 non-randomized open-label trial (McGowan et al., Journal of Psychopharmacology) found single-dose psilocybin (25 mg) to be safe, well-tolerated, and associated with symptomatic improvement in adults with PTSD. This is Phase 1–2 level evidence, not efficacy-confirming data.

End-of-life anxiety: The Johns Hopkins psilocybin research has historically shown the strongest effects in this population. A landmark double-blind crossover trial in cancer patients found that high-dose psilocybin produced substantial reductions in cancer-related existential distress that persisted at 6-month follow-up.

Johns Hopkins Center for Psychedelic and Consciousness Research (research summary, 2024): "In our trials, psilocybin with psychological support produces large-magnitude reductions in depression and anxiety that persist for months after a single or double session. The effect sizes we see are substantially larger than those typically seen with conventional antidepressants."

What the clinical evidence does NOT show: Psilocybin therapy is not effective for everyone. The remission data reflects a meaningful subset. It does not work in the absence of psychological support, the therapeutic container, not the molecule alone, drives outcomes. No evidence exists for unguided, unsupported psilocybin use as a therapeutic intervention.

Who Should Avoid Psilocybin Therapy Tourism?

Every legitimate provider across all three legal jurisdictions uses a medical screening protocol derived from the same core contraindication list. Knowing this list is not optional. Misrepresenting your history to pass screening increases your risk of an acute adverse event in a foreign country with limited emergency psychiatric infrastructure.

Absolute contraindications (all legal providers screen for these):

• Personal history of schizophrenia, schizoaffective disorder, or bipolar I disorder
• First-degree family history of schizophrenia or schizoaffective disorder (significantly elevated risk of latent susceptibility)
• Current use of lithium (risk of neurotoxicity and seizure in combination with serotonergic psychedelics)
• Current use of MAOIs (monoamine oxidase inhibitors; risk of serotonin syndrome)
• Uncontrolled cardiovascular disease, unstable angina, or recent myocardial infarction (psilocybin elevates heart rate and blood pressure during the session)
• Active suicidality with plan or intent (high-dose altered-state experience is contraindicated in acute risk)
• Pregnancy

Relative contraindications (require case-by-case medical evaluation):

• History of bipolar II disorder or hypomania
• Current use of SSRIs (reduces psilocybin efficacy; SSRIs are typically tapered 2 weeks before a session under medical supervision)
• History of seizure disorders
• Severe liver disease
• First-time psychedelic use with pre-existing anxiety disorders (manageable with appropriate preparation, but requires an experienced facilitator)

What poor screening looks like: A retreat that accepts bookings without asking about medications, family psychiatric history, or cardiovascular status is not running adequate screening. This is a red flag that correlates with poor integration support and lower-quality facilitation overall.

How does medical tourism insurance interact with alternative therapy complications? Read our medical tourism insurance guide.

Photo by daven Hsu on Unsplash

How Do I Choose Between Oregon, Jamaica, and Netherlands?

The decision framework comes down to four variables: clinical structure required, budget, schedule flexibility, and travel preference.

	Oregon (Measure 109)	Jamaica Retreat	Netherlands Truffles
Legal basis	ORS Chapter 475A (Measure 109)	Dangerous Drugs Act Ch. 201B (not scheduled)	Dutch Opium Act (sclerotia not listed)
Cost (total, 2026)	$1,500–$4,500 USD	$2,500–$8,500 USD	€350–€1,200 (group); €1,700+ (private)
Dosing model	State-licensed standardized psilocybin product, known potency	Psilocybe mushrooms, variable potency	Psilocybe sclerotia (truffles), variable potency
Facilitator licensing	State-required (OHA-licensed)	None required by law	None required by law
Medical screening required	Yes (OHA rules)	Varies by operator (best operators: physician-administered)	Varies by operator
Integration support	Required by state rules	Varies by operator (included at quality retreats)	Varies by operator (most include same-day integration)
Number of sessions	Typically 1 (multi-session packages available)	Typically 2–3 sessions over 5–8 days	Typically 1–2
International travel required	No (for US residents)	Yes	Yes
Diagnosis required	No	No	No
Who fits best	US residents wanting regulated, licensed care; TRD or PTSD with formal clinical context	Those wanting immersive multi-day retreat format with therapeutic community; comfortable with operator-level (not state-level) vetting	Budget-conscious; seeking a single guided session; comfortable with operator self-regulation; already in Europe

Choose Oregon if: You are a US resident, you want a state-licensed facilitator, you have a documented clinical history you want overseen by a licensed practitioner, and you can tolerate a 4–12 week waitlist. The Measure 109 framework provides the closest analog to a clinical trial experience in a non-prescription setting.

Choose Jamaica if: You want a multi-day retreat container with group therapy elements, you are comfortable investing $5,000–$8,000 in a full-service program, and you are willing to rigorously vet the operator rather than relying on state oversight. Jamaica's best retreats (MycoMeditations, Beckley, ONE Retreats) are genuinely clinical-quality operations.

Choose Netherlands if: You are traveling in Europe or want the lowest-cost legal option, you are comfortable with a single-day or weekend format, and you are prepared to independently vet the operator's screening and integration protocols. The Netherlands is also the best option for travelers who have existing experience with psychedelics and want a lighter therapeutic touch rather than a full immersive retreat.

A note on Travel Anywhere for pre-trip logistics: The preparation for any psilocybin therapy journey (screening, accommodation near the service center, pre-session and post-session schedule) is complex multi-variable planning. travelanywhere.chat can map the logistics across all three destinations in a single workflow, including accommodation options proximate to Oregon service centers, Jamaican retreat transfer logistics, and Amsterdam accommodation within walking distance of ceremony operators.

Explore how IVF tourism country-to-country comparison maps to this kind of legal and cost analysis.

Bottom Line: The 2026 Psilocybin Therapy Tourism Decision

This is not a market you enter with a Google search and a credit card. The three legal pathways exist on a spectrum from state-regulated clinical framework (Oregon) to operator-regulated retreat market (Jamaica) to legally permissive but entirely self-governed ceremony market (Netherlands). Each is legitimate. Each has produced meaningful therapeutic outcomes. Each carries meaningfully different risks if you select a low-quality operator or misrepresent your medical history.

The clinical evidence is strong enough that it is reasonable to pursue psilocybin-assisted therapy in 2026 if you have treatment-resistant depression, PTSD, or end-of-life anxiety and conventional treatments have not worked. A Hedges' g of -1.27 in TRD is a large effect. A 58% remission rate at 12 months in Veterans with severe TRD is not a placebo finding.

The decisions that determine whether you have a beneficial or an adverse experience are: choosing a provider that runs rigorous medical screening, being honest in that screening, arriving with preparation and clear intentions, and having a qualified integration practitioner scheduled for follow-up before you board the plane.

Travel Anywhere is the AI-powered travel planning platform at travelanywhere.chat that helps health travelers plan the full logistics of international wellness trips: provider vetting frameworks, accommodation, and itinerary. Use it to plan the travel architecture around whichever pathway you choose.

---

FAQ: Psilocybin Therapy Tourism in 2026

Is psilocybin therapy legal for US citizens traveling to Jamaica or the Netherlands? Yes. US citizens can legally participate in psilocybin ceremonies in Jamaica and psilocybin truffle ceremonies in the Netherlands. These activities are legal under the laws of each destination country. US federal law does not extend extraterritorially to personal activities abroad. The legal risk is at re-entry: importing psilocybin or mushrooms into the US remains a federal Schedule I drug offense. No legitimate provider expects or encourages participants to bring anything home.

Will travel insurance cover a psilocybin therapy retreat? Standard travel insurance does not cover the cost of the therapy program itself. Medical evacuation coverage and emergency medical insurance remain active for physical emergencies that occur during the trip: a cardiac event at a retreat would be covered under a robust travel insurance policy. The therapy cost itself is out-of-pocket and non-refundable in most provider contracts.

How many sessions does it typically take to see results? The clinical literature is predominantly single-session and two-session data. The landmark Johns Hopkins and COMPASS Pathways trials used one or two psilocybin sessions with intensive psychotherapeutic support. Oregon service centers typically offer single sessions, with some providers offering two-session packages. Jamaican retreats typically include two to three sessions over a multi-day program.

Can I do psilocybin therapy if I'm currently on an SSRI? Most providers require an SSRI taper (typically two weeks) before the administration session, because SSRIs appear to substantially reduce psilocybin's therapeutic effects via 5-HT2A receptor downregulation. This should be done under physician supervision, not unilaterally. A provider that does not ask about SSRI use is not running adequate screening.

What is the difference between a psilocybin "retreat" and "therapy"? In Oregon, facilitators can legally offer "psilocybin services" but are prohibited from practicing medicine or psychotherapy as part of the service. In Jamaica and the Netherlands, unregulated operators use a range of terms. Functionally, what distinguishes therapy-grade programs from retreat-grade programs is: physician-administered pre-session screening, presence of licensed mental health professionals or trained therapists, structured integration protocol, and clear emergency escalation procedures. "Therapy" in the context of psilocybin tourism is a quality signal to interrogate, not a guaranteed standard.

How far in advance do I need to book? Oregon service centers in 2026 are running 4–12 week waitlists for most licensed providers. Jamaican retreats book 4–8 weeks out for structured multi-day programs; peak winter season requires further advance notice. Amsterdam truffle ceremony providers can sometimes accommodate bookings 1–2 weeks in advance for group formats. Budget 6–8 weeks of lead time across all three destinations for proper preparation.

Is there a minimum age? Oregon Measure 109 prohibits providing psilocybin services to anyone under 21. Jamaican retreats universally require participants to be at least 18, with most established operators requiring 21 and parental consent for under-21 participants. Dutch ceremony operators require a minimum age of 18. Participants over 65 are generally eligible but should disclose cardiovascular history fully during medical screening.

---

Ready to make this trip happen? Travel Anywhere plans and books everything — start to finish. Begin at travelanywhere.chat.

Sources

1. Oregon Health Authority. Oregon Psilocybin Services: ORS Chapter 475A (Measure 109). oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx
2. Oregon Revised Statutes Chapter 475A (Psilocybin Services Act). oregonlegislature.gov/bills_laws/ors/ors475a.html
3. Oregon Public Broadcasting. A third of Oregon's licensed psilocybin service centers have closed. OPB.org, January 22, 2026.
4. Meikle, S. et al. Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial. Journal of Psychopharmacology. Sagepub, 2025. doi:10.1177/20451253251377187
5. McGowan, N.M. et al. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. Journal of Psychopharmacology. Sagepub, 2025. doi:10.1177/02698811251362390
6. Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study. ScienceDirect, 2025.
7. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial. PubMed/JAMA, 2026. PMID:41848690
8. Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder: A dose-response network meta-analysis of randomized placebo-controlled clinical trials. ScienceDirect, 2024.
9. Trimbos Institute. National Drug Monitor 2023: Psychedelics and Truffle Ceremonies in the Netherlands. trimbos.nl. Utrecht: Trimbos-instituut, 2023.
10. Dangerous Drugs Act of Jamaica, Chapter 201B. jamaicalegislation.gov.jm (via UNODC Legislative Database).
11. Dutch Opium Act (Opiumwet), Schedules I and II, as amended 1999. wetten.overheid.nl.
12. Johns Hopkins Center for Psychedelic and Consciousness Research. Research Summary: Psilocybin Studies 2006–2024. hopkinsmedicine.org/psychiatry/research/psychedelics-research
13. Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine. PMC/NCBI, 2026. PMC12681608.
14. MycoMeditations. 2026 Retreat Pricing and Program Structure. mycomeditations.com